Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought...

Related Keywords

Memorial Sloan Kettering Cancer Center ,New York ,United States ,Colorado ,California ,Los Angeles ,Heather Landau ,Mike Moyer ,Gabriel Morris ,Ilya Rachman ,Amyloidosis Program ,Exchange Commission ,Company Contact ,University Of Colorado ,Nexcella Inc ,Immix Biopharma Inc ,Nasdaq ,Nexcella Scientific Advisory Board ,Nexcella Scientific Advisory ,Chief Executive Officer ,Chief Financial Officer ,Immix Biopharma ,Bone Marrow Transplant Specialist ,Cellular Therapist ,Medical University ,Internal Medicine ,Memorial Sloan Kettering Cancer ,Tissue Specific Therapeutics ,Tissue Specific Therapeutic ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Risk Factor ,Annual Report ,Markets ,